UBS raised the firm’s price target on DocuSign (DOCU) to $85 from $80 and keeps a Neutral rating on the shares. Stronger renewal activity drove a big billings beat in Q2, the analyst tells investors in a research note. The firm says the Q2 print “comes as a relief.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCU: